Log In
BCIQ
Print this Print this
 

Coversin

  Manage Alerts
Collapse Summary General Information
Company Akari Therapeutics plc
DescriptionComplement 5 (C5) inhibitor, which prevents the release of C5a and formation of complement C5b-9 membrane attack complex (MAC)
Molecular Target Complement 5 (C5)
Mechanism of ActionComplement inhibitor
Therapeutic ModalityBiologic: Protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$6.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/14/2016

Undisclosed

Undisclosed

Undisclosed

09/18/2015

Undisclosed

$6.0M

0

Get a free BioCentury trial today